Highlights
A phase 3 randomized clinical trial involving 196 patients has demonstrated that stereotactic radiation (SR) significantly improves patient-reported symptom severity compared to hippocampal-avoidance whole brain radiation (HA-WBRT) for those with 5 to 20 brain metastases.
Patients receiving SR experienced a mean improvement in symptom scores (-0.32), whereas those receiving HA-WBRT experienced a worsening of symptoms (+0.74), resulting in a clinically meaningful difference of -1.06.
